Poor
Mostly Unaligned
Patient Risk:
Medium
Summary
Only one core clinical statement is supported by the provided label text (indication as adjunct to diet/exercise for glycemic control in adults with type 2 diabetes). Several other claims (price/discounts, generic availability timing, manufacturer, common side effects, and Janumet relationship) are not supported by the supplied prescribing-information excerpts and some may be inconsistent with what is actually included in those excerpts.
Category Scores
Accurate Statements
Januvia is a prescription medication used to treat type 2 diabetes by helping to control blood sugar levels.
1 INDICATIONS AND USAGE: JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Unsupported Statements
The average retail price for a 30-day supply of Januvia (sitagliptin) 100 mg without insurance is approximately $470.
No pricing information is provided in the supplied prescribing-information excerpts.
Januvia price can vary based on insurance coverage, pharmacy, and location.
No statement about pricing variability is provided in the supplied label excerpts.
Patient assistance programs and discount coupons can reduce the out-of-pocket cost of Januvia.
No patient assistance/discount/coupon information is provided in the supplied label excerpts.
A manufacturer coupon may lower the cost of Januvia to as little as $10 for eligible commercially insured patients for up to a 12-month supply.
No coupon/program pricing terms are provided in the supplied label excerpts.
Websites like SingleCare can offer discounts on Januvia, potentially bringing the price down to around $350-$400 for a 30-day supply.
No third-party discount or website pricing is provided in the supplied label excerpts.
Generic versions of sitagliptin began becoming available in the United States in early 2023.
No information about generic availability dates is provided in the supplied label excerpts.
The availability of generics typically leads to a decrease in the price of the brand-name drug over time.
No market pricing/competition statements are provided in the supplied label excerpts.
Januvia is manufactured by Merck & Co.
No manufacturer/company information is provided in the supplied label excerpts.
Common side effects of Januvia can include nasopharyngitis (common cold symptoms), headache, and diarrhea.
The supplied label excerpts list adverse reactions discussed elsewhere (e.g., pancreatitis, heart failure, acute renal failure, hypoglycemia with insulin/secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid), but do not provide 'common side effects' or a list including nasopharyngitis, headache, and diarrhea.
More serious, though rare, side effects of Januvia can include pancreatitis, severe joint pain, and allergic reactions.
While pancreatitis, severe and disabling arthralgia, and hypersensitivity reactions are listed as adverse reactions/warnings elsewhere, the supplied excerpts do not support the characterization that these are 'rare' and do not define 'more serious, though rare' for these items.
Janumet is a combination medication that contains sitagliptin and metformin.
No Janumet composition information is provided in the supplied label excerpts for Januvia.
Janumet is prescribed for patients who may benefit from both sitagliptin and metformin to control their blood sugar.
No Janumet indication information is provided in the supplied label excerpts.
Janumet's price differs from Januvia because it is a combination of drugs.
No pricing rationale/comparison is provided in the supplied label excerpts.
Contradictions
Important Omissions
Dose, dosing frequency, dose adjustments, and administration instructions for Januvia.
Importance:
Moderate
Important contraindications and boxed warnings (if any) from the full labeling.
Importance:
Moderate
Drug interactions and specific-population safety statements (e.g., pregnancy, pediatric, lactation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some safety-related statements are partially supported (pancreatitis, hypersensitivity reactions, severe arthralgia are referenced in the supplied label excerpts), but key safety labeling details such as contraindications, full warnings/precautions, and adverse reaction incidence are not addressed. Additionally, several statements (especially 'common' vs 'rare' side effect characterization and pricing/generic availability) are unsupported by the provided label excerpts, which may distract from label-accurate counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple claims are unsupported because the supplied prescribing-information excerpts do not contain pricing/discount, generic availability timing, manufacturer identity, or the specified 'common side effects' list; only the general glycemic-control indication statement is supported.
Suggested Improvement
Restrict claims to label-supported content present in the provided excerpts (e.g., adjunct to diet/exercise to improve glycemic control in adults with type 2 diabetes; pancreatitis/hypersensitivity/severe arthralgia as discussed elsewhere). Remove or qualify unsupported pricing, discount, generic timing, manufacturer, and side-effect frequency/necessity claims unless the complete label sections are provided and can support them.